|Table of Contents|

Research progress on the interaction between dendritic cells and PD-1/PD-L1 pathway

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 07
Page:
1366-1370
Research Field:
Publishing date:

Info

Title:
Research progress on the interaction between dendritic cells and PD-1/PD-L1 pathway
Author(s):
TAO Han; XU Yuqing
The Second Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150000,China.
Keywords:
dendritic cells(DCs); PD-1/PD-L1 signaling pathway; tumor immunity; combination therapy
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2023.07.038
Abstract:
Dendritic cells(DCs) are the most powerful antigen-presenting cells,which have the ability to cause antigen-specific responses and play an important role in regulating immune tolerance.DCs-based cancer immunotherapy has been studied for more than 20 years and is one of the most important anti-cancer immunotherapies.However,the effect of monotherapy in cancer treatment is limited.In-depth research is needed to improve the anti-tumor effect of DCs and look for synergistic treatment with other methods.Monoclonal antibodies targeted at immune checkpoints have been successful in clinical trials of recognized solid and hematological malignancies,and won the Nobel Prize in Medicine in 2018.Immune checkpoint blocking therapy aims to relieve the immunosuppression of tumors to enhance the anti-tumor effect of the immune system.Among them,blocking therapy for PD-1/PD-L1 immune checkpoints has attracted considerable attention.Although the effect of immune checkpoint blocking therapy is encouraging,further research is still needed to improve clinical efficiency in areas that have not yet met the medical needs.Theoretically,the silencing or down-regulation of PD-L1 of DCs and/or PD-1 of T cells can enhance DCs to initiate effective T cell anti-tumor response.Therefore,the combination of specific DCs anti-tumor immunotherapy and PD-1/PD-L1 signaling pathway blockade is a promising way to explore.This article will mainly review the current research status and prospects of the function of DCs,the anti-tumor effect of PD-1/PD-L1 pathway,and the interaction between DCs and PD-1/PD-L1 signaling pathway.

References:

［1］YU XR,WEN QS,XIAO Y，et al.Blocking programmed death-ligand 1 attenuates maturation inhibition of dendritic cells by co-cultured breast cancer cells［J］.Journal of Southern Medical University,2018,38(5):561-566.
［2］ZHAO X,WEI Y,CHU YY，et al.Phosphorylation and stabilization of PD-L1 by CK2 suppresses dendritic cell function［J］.Cancer Research,2022,82(11):2185-2195.
［3］SUN C,MEZZADRA R,SCHUMACHER TN.Regulation and function of the PD-L1 checkpoint［J］.Immunity,2018,48(3):434-452.
［4］ALSAAB HO,SAU S,ALZHRANI R，et al.PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy:Mechanism,combinations,and clinical outcome［J］.Frontiers in Pharmacology,2017,8:561.
［5］SANTOS PM,BUTTERFIELD LH.Dendritic cell-based cancer vaccines［J］.Journal of Immunology,2018,200(2):443-449.
［6］KONG BY,BOLTON H,KIM JW，et al.On the other side:Manipulating the immune checkpoint landscape of dendritic cells to enhance cancer immunotherapy［J］.Frontiers in Oncology,2019,9:50.
［7］LUAN YY,ZHANG L,ZHU FJ，et al.Effect of TIPE1 on immune function of dendritic cells and its signaling pathway in septic mice［J］.The Journal of Infectious Diseases,2019,220(4):699-709.
［8］QIAN C,CAO X.Dendritic cells in the regulation of immunity and inflammation［J］.Seminars in Immunology,2018,35:3-11.
［9］CONSTANTINO J,GOMES C,FALCAO A，et al.Dendritic cell-based immunotherapy:a basic review and recent advances［J］.Immunologic Research,2017,65(4):798-810.
［10］FU C,JIANG A.Dendritic cells and CD8 T cell immunity in tumor microenvironment［J］.Frontiers in Immunology,2018,9:3059.
［11］BOL KF,SCHREIBELT G,GERRITSEN WR，et al.Dendritic cell-based immunotherapy:State of the art and beyond［J］.Clinical Cancer Research,2016,22(8):1897-1906.
［12］VERSTEVEN M,VAN DEN BERGH JMJ,MARCQ E，et al.Dendritic cells and programmed death-1 blockade:A joint venture to combat cancer［J］.Frontiers in Immunology,2018,9:394.
［13］RANDOLPH GJ.Dendritic cells:The first step［J］.The Journal of Experimental Medicine,2021,218:3.
［14］SUN NY,CHEN YL,WU WY，et al.Blockade of PD-L1 enhances cancer immunotherapy by regulating dendritic cell maturation and macrophage polarization［J］.Cancers,2019,11(9):1400.
［15］MAYOUX M,ROLLER A,PULKO V，et al.Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy［J］.Science Translational Medicine,2020,12(534):eaav7431.
［16］HSU FJ,BENIKE C,FAGNONI F，et al.Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells［J］.Nature Medicine,1996,2(1):52-58.
［17］YI M,ZHENG X,NIU M，et al.Combination strategies with PD-1/PD-L1 blockade:current advances and future directions［J］.Molecular Cancer,2022,21(1):28.
［18］HASSANNIA H,GHASEMI CHALESHTARI M,ATYABI F，et al.Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine［J］.Immunology,2020,159(1):75-87.
［19］LIU J,CHEN Z,LI Y，et al.PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy［J］.Frontiers in Pharmacology,2021,12:731798.
［20］PHILIPS GK,ATKINS M.Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies［J］.International Immunology,2015,27(1):39-46.
［21］SWAIKA A,HAMMOND WA,JOSEPH RW.Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy［J］.Molecular Immunology,2015,67(2 Pt A):4-17.
［22］BALAR AV,WEBER JS.PD-1 and PD-L1 antibodies in cancer:current status and future directions［J］.Cancer Immunology,Immunotherapy,2017,66(5):551-564.
［23］JIANG Y,CHEN M,NIE H，et al.PD-1 and PD-L1 in cancer immunotherapy:clinical implications and future considerations［J］.Human Vaccines & Immunotherapeutics,2019,15(5):1111-1122.
［24］HOY SM.Sintilimab:First global approval［J］.Drugs,2019,79(3):341-346.
［25］罗详冲,李高峰.特瑞普利单抗在恶性肿瘤治疗中的应用［J］.中国肿瘤生物治疗杂志,2020,27(08):946-950. LUO XC,LI GF.Application of toripalimab in the treatment of malignant tumors［J］.Chinses Journal of Cancer Biotherapy，2020,27(08):946-950.
［26］MARKHAM A,KEAM SJ.Camrelizumab:First global approval［J］.Drugs,2019,79(12):1355-1361.
［27］LEE A,KEAM SJ.Tislelizumab:First approval［J］.Drugs,2020,80(6):617-624.
［28］SEYA T,TAKEDA Y,TAKASHIMA K，et al.Adjuvant immunotherapy for cancer:both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy［J］.Proceedings of the Japan Academy Series B,Physical and Biological Sciences,2018,94(3):153-160.
［29］NAGAOKA K,HOSOI A,IINO T，et al.Dendritic cell vaccine induces antigen-specific CD8(+) T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade［J］.Oncoimmunology,2018,7(3):e1395124.
［30］CHARLES J,CHAPEROT L,HANNANI D，et al.An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial［J］.Oncoimmunology,2020,9(1):1738812.
［31］LINCH SN,REDMOND WL.How do I steer this thing? Using dendritic cell targeted vaccination to more effectively guide the antitumor immune response with combination immunotherapy［J］.Journal for Immunotherapy of Cancer,2016,4:31.
［32］LIU Q,LU JY,WANG XH，et al.Changes in the PD-1 and PD-L1 expressions of splenic dendritic cells in multiple-organ dysfunction syndrome mice and their significance［J］.Genetics and Molecular Research,2014,13(3):7666-7672.
［33］WANG J,SUN M,ZHU X，et al.Lentivirus-mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti-tumor effect of dendritic cell vaccination against pancreatic cancer in SCID-hu mice［J］.Oncology Letters,2019,18(2):1539-1547.
［34］CURIEL TJ,WEI S,DONG H，et al.Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity［J］.Nature Medicine,2003,9(5):562-567.
［35］GE Y,XI H,JU S，et al.Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice［J］.Cancer Letters,2013,336(2):253-259.
［36］LIU Q,LV Y,ZHAO M，et al.PD-L1 blockade improves immune dysfunction of spleen dendritic cells and T-cells in zymosan-induced multiple organs dysfunction syndromes［J］.International Journal of Clinical and Experimental Pathology,2015,8(2):1374-1383.
［37］GARRIS CS,ARLAUCKAS SP,KOHLER RH，et al.Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12［J］.Immunity,2018,49(6):1148-1161.
［38］MA X,GUO Z,WEI X，et al.Spatial distribution and predictive significance of dendritic cells and macrophages in esophageal cancer treated with combined chemoradiotherapy and PD-1 blockade［J］.Frontiers in Immunology,2021,12:786429.
［39］GARG AD,VARA PEREZ M,SCHAAF M，et al.Trial watch:Dendritic cell-based anticancer immunotherapy［J］.Oncoimmunology,2017,6(7):e1328341.
［40］INO Y,YAMAZAKI-ITOH R,SHIMADA K，et al.Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer［J］.British Journal of Cancer,2013,108(4):914-923.
［41］FU J,MALM IJ,KADAYAKKARA DK，et al.Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors［J］.Cancer Research,2014,74(15):4042-4052.
［42］SIERRO SR,DONDA A,PERRET R，et al.Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity［J］.European Journal of Immunology,2011,41(8):2217-2228.
［43］MORSE MA,LYERLY HK.Checkpoint blockade in combination with cancer vaccines［J］.Vaccine,2015,33(51):7377-7385.
［44］BASSANI-STERNBERG M,DIGKLIA A,HUBER F，et al.A phase Ib study of the combination of personalized autologous dendritic cell vaccine,aspirin,and standard of care adjuvant chemotherapy followed by nivolumab for resected pancreatic adenocarcinoma-A proof of antigen discovery feasibility in three patients［J］.Frontiers in Immunology,2019,10:1832.
［45］DRAUBE A,KLEIN-GONZLEZ N,MATTHEUS S，et al.Dendritic cell based tumor vaccination in prostate and renal cell cancer:a systematic review and meta-analysis［J］.PloS One,2011,6(4):e18801.
［46］BOUDEWIJNS S,WESTDORP H,KOORNSTRA RH,et al.Immune-related adverse events of dendritic cell vaccination correlate with immunologic and clinical outcome in stage III and IV melanoma patients［J］.Journal of Immunotherapy,2016,39(6):241-248.

Memo

Memo:
-
Last Update: 2023-02-28